We are analyzing https://link.springer.com/article/10.1007/s002620050498.

Title:
Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer | Cancer Immunology, Immunotherapy
Description:
This paper reviews the use of low-dose cyclophosphamide (CY) with active specific immunotherapy in patients with advanced melanoma and other metastatic cancers, and outlines the basic scientific research that supports this use. In various animal models, CY augments delayed-type hypersensitivity responses, increases antibody production, abrogates tolerance, and potentiates antitumor immunity. The mechanism of CY immunopotentiation involves inhibition of a suppressor function, as indicated by extensive work in the MOPC-315 plasmacytoma murine model. Human studies of the immunopotentiating effect of CY have yielded both positive and negative results. Toxicity associated with low-dose CY has been mild in these studies. Results of efficacy have been variable for reasons such as small sample sizes, short follow-up periods, and the weaker immunogenicity of human tumor-associated antigens. Although beneficial clinical outcomes have been observed in historically controlled trials, there are few randomized, controlled trials that evaluate outcome in relation to CY immunopotentiation of active specific immunotherapy. Additional randomized, controlled trials should be done to examine the clinical efficacy of CY immunopotentiation of therapeutic cancer vaccines.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Non-Profit & Charity
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, immunotherapy, article, privacy, cookies, content, immunopotentiation, cyclophosphamide, active, specific, access, information, publish, research, search, lowdose, clinical, data, log, journal, bass, mastrangelo, controlled, trials, discover, springer, function, optional, personal, parties, policy, find, track, immunology, cite, katherine, michael, explore, melanoma, basic, human, studies, effect, results, efficacy, randomized, additional, institution, open, chapter,

Topics {✒️}

month download article/chapter active specific immunotherapy article cancer immunology beneficial clinical outcomes privacy choices/manage cookies basic scientific research related subjects cancer review published therapeutic cancer vaccines full article pdf low-dose cyclophosphamide european economic area increases antibody production potentiates antitumor immunity small sample sizes low-dose cy conditions privacy policy advanced melanoma jefferson medical college check access instant access accepting optional cookies historically controlled trials journal finder publish immunotherapy aims clinical efficacy article log article bass privacy policy personal data article cite books a cy immunopotentiation optional cookies manage preferences subscription content similar content cancer controlled trials data protection essential cookies cookies skip additional randomized medical oncology institution subscribe journal publish cyclophosphamide usage analysis social media varying standards

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
         description: This paper reviews the use of low-dose cyclophosphamide (CY) with active specific immunotherapy in patients with advanced melanoma and other metastatic cancers, and outlines the basic scientific research that supports this use. In various animal models, CY augments delayed-type hypersensitivity responses, increases antibody production, abrogates tolerance, and potentiates antitumor immunity. The mechanism of CY immunopotentiation involves inhibition of a suppressor function, as indicated by extensive work in the MOPC-315 plasmacytoma murine model. Human studies of the immunopotentiating effect of CY have yielded both positive and negative results. Toxicity associated with low-dose CY has been mild in these studies. Results of efficacy have been variable for reasons such as small sample sizes, short follow-up periods, and the weaker immunogenicity of human tumor-associated antigens. Although beneficial clinical outcomes have been observed in historically controlled trials, there are few randomized, controlled trials that evaluate outcome in relation to CY immunopotentiation of active specific immunotherapy. Additional randomized, controlled trials should be done to examine the clinical efficacy of CY immunopotentiation of therapeutic cancer vaccines.
         datePublished:
         dateModified:
         pageStart:1
         pageEnd:12
         sameAs:https://doi.org/10.1007/s002620050498
         keywords:
            Key words Cyclophosphamide
            Active specific immunotherapy
            Vaccine
            Theraccine
            Melanoma
            Oncology
            Immunology
            Cancer Research
         image:
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:47
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Katherine K. Bass
               affiliation:
                     name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
                     address:
                        name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael J. Mastrangelo
               affiliation:
                     name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
                     address:
                        name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer
      description: This paper reviews the use of low-dose cyclophosphamide (CY) with active specific immunotherapy in patients with advanced melanoma and other metastatic cancers, and outlines the basic scientific research that supports this use. In various animal models, CY augments delayed-type hypersensitivity responses, increases antibody production, abrogates tolerance, and potentiates antitumor immunity. The mechanism of CY immunopotentiation involves inhibition of a suppressor function, as indicated by extensive work in the MOPC-315 plasmacytoma murine model. Human studies of the immunopotentiating effect of CY have yielded both positive and negative results. Toxicity associated with low-dose CY has been mild in these studies. Results of efficacy have been variable for reasons such as small sample sizes, short follow-up periods, and the weaker immunogenicity of human tumor-associated antigens. Although beneficial clinical outcomes have been observed in historically controlled trials, there are few randomized, controlled trials that evaluate outcome in relation to CY immunopotentiation of active specific immunotherapy. Additional randomized, controlled trials should be done to examine the clinical efficacy of CY immunopotentiation of therapeutic cancer vaccines.
      datePublished:
      dateModified:
      pageStart:1
      pageEnd:12
      sameAs:https://doi.org/10.1007/s002620050498
      keywords:
         Key words Cyclophosphamide
         Active specific immunotherapy
         Vaccine
         Theraccine
         Melanoma
         Oncology
         Immunology
         Cancer Research
      image:
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:47
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Katherine K. Bass
            affiliation:
                  name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
                  address:
                     name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael J. Mastrangelo
            affiliation:
                  name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
                  address:
                     name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:47
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
      address:
         name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
         type:PostalAddress
      name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
      address:
         name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Katherine K. Bass
      affiliation:
            name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
            address:
               name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
               type:PostalAddress
            type:Organization
      name:Michael J. Mastrangelo
      affiliation:
            name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
            address:
               name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
      name:Division of Medical Oncology, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA, , US
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(27)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.87s.

LINK . SPRINGER . COM {}